1 / 28

Enzo Manzato

Iperuricemia con deposito di urato: nuovi approcci terapeutici. Enzo Manzato. Uricemia ≤ 5,1 mg/dl. Uricemia > 5,1 mg/dl. HR = 1,30 (IC 95% 1,13-1,51). anni. n = 2.910; follow-up 4,4 anni. Diabetes Care 32, 153, 2009. Uricemia ≤ 5,1 mg/dl. sopravvivenza cumulata.

rehan
Download Presentation

Enzo Manzato

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Iperuricemia con deposito di urato: nuovi approcci terapeutici Enzo Manzato

  2. Uricemia ≤ 5,1 mg/dl Uricemia > 5,1 mg/dl HR = 1,30 (IC 95% 1,13-1,51) anni • n = 2.910; follow-up 4,4 anni Diabetes Care 32, 153, 2009

  3. Uricemia ≤ 5,1 mg/dl sopravvivenza cumulata Uricemia > 5,1 mg/dl HR = 1,30 (IC 95% 1,13-1,51) anni • n = 2.910; follow-up 4,4 anni Diabetes Care 32, 153, 2009

  4. Uricemia ≤ 5,1 mg/dl Sindrome Metabolica NO sopravvivenza cumulata Uricemia > 5,1 mg/dl Sindrome Metabolica SÌ HR = 1,30 (IC 95% 1,13-1,51) HR=1,25 (p<0,01) anni • n = 2.910; follow-up 4,4 anni Diabetes Care 32, 153, 2009

  5. Cardiovascular Conditions and Risk Factors Associated with Elevated Uric Acid • - Hypertensionand prehypertension • - Renal disease (including reduced glomerular filtration rate and microalbuminuria) • -Metabolic syndrome (including abdominal obesity, hypertriglyceridemia, low level of HDL • cholesterol, insulin resistance, impaired glucose tolerance, elevated leptin level) • - Obstructivesleep apnea • - Vasculardisease (carotid, peripheral, coronaryartery) • - Strokeand vasculardementia • - Preeclampsia • - Inflammationmarkers (CRP, PAI 1 inhibitor, s-ICAM 1) • - Endothelialdysfunction • - Oxidativestress • - Sex and race (postmenopausal women, blacks) • - Demographic (movement from rural to urban communities, Westernization, immigration to • Western cultures) N Engl J Med359, 1811, 2008

  6. Q1 > 4,22 Q2 4,22 - 4,74 Q3 4,74 - 5,50 Q4 5,50 - 6,41 Q5 > 6,41 mg/dl n = 4.385; follow-up 8,4 anni Stroke 37, 1503, 2006

  7. HealthProfessionals Follow-up Study * * RISCHIO RELATIVO MULTIVARIATO SENZA GOTTA CON GOTTA SENZA GOTTA CON GOTTA CON PRECEDENTE CHD SENZA PRECEDENTE CHD n = 51.297; follow-up 12 anni Circulation 116, 894, 2007

  8. HealthProfessionals Follow-up Study * * RISCHIO RELATIVO MULTIVARIATO SENZA GOTTA CON GOTTA SENZA GOTTA CON GOTTA CON PRECEDENTE CHD SENZA PRECEDENTE CHD n = 51.297; follow-up 12 anni Circulation 116, 894, 2007

  9. HealthProfessionals Follow-up Study Rischio di diabete aggiustato per età, sesso, IMC, circonferenza vita, pressione arteriosa e colesterolo HDL per quartili di acido urico Rischio relativo di diabete 5,22-6,22 4,50-5,21 ≤ 4,49 ≥ 6,23 mg/dl ACIDO URICO p for trend < 0.001 n = 4.536; follow-up 10,1 anni Diabetes Care 31, 361, 2008

  10. Framingham Heart Study original (n 4883) and offspring (n 4292) cohorts aged 29-62 years at time of recruitment in 1948, followedbiennially, 26° examination [2000-2002] for the original cohort relative risk of incident diabetes mg/dL URIC ACID relative risk of incident diabetes adjusting for age, sex, physical activity, alcohol consumption, smoking, hypertension, body mass index, and blood levels of glucose, cholesterol, creatinine, and triglycerides. Am J Med 123, 957, 2010

  11. Evidence Linking Uric Acid and Hypertension • - An elevated uric acid level consistently predicts the development of hypertension. • - An elevated uric acid level is observed in 25–60% of patients with untreated essential • hypertension and in nearly 90% of adolescents with essential hypertensionof recentonset. • - Raising the uric acid level in rodents results in hypertension with the clinical, hemodynamic, and histologic characteristics of hypertension. • - Reducing the uric acid level with xanthine oxidase inhibitors lowers blood pressure in adolescents with hypertension of recent onset. N Engl J Med359, 1811, 2008

  12. Veterans Administration - Boston Multivariable-adjustedassociationof baseline serum uric acid level with incidenthypertension p trend = 0,02 Relative risk mg/dl uric acid n = 2.062; follow-up 21,5 anni Hypertension 48, 1031, 2006

  13. n = 30 adolescents (aged 11-17 years) with newlydiagnosedessentialhypertension and uric acid >6 mg/dl, treated for 4 weeks with allopurinol 200 mg twicedaily JAMA 300, 924, 2008

  14. n = 30 adolescents (aged 11-17 years) with newlydiagnosedessentialhypertension and uric acid >6 mg/dl, treated for 4 weeks with allopurinol 200 mg twicedaily JAMA 300, 924, 2008

  15. Change in total exercise time from baseline n = 65 patients with angiographicallydocumentedcoronaryarterydisease Lancet 375, 2161, 2010

  16. J Clin Invest 120, 1791, 2010

  17. CASO CLINICO Arch Gerontology Geriat 55, 497, 2012

  18. CASO CLINICO Arch Gerontology Geriat 55, 497, 2012

  19. PharmReviews 58, 87, 2006

  20. % patients with uric acid <6 mg/dl at last visit p < 0.001 % patients N Engl J Med353, 2450, 2005

  21. Subjects Requiring Treatment for Gout Flares N Engl J Med353, 2450, 2005

  22. Proportion of subjects with serum uratelevels <6.0 mg/dl at final visit Proportion of subjects (%) Arthritis & Rheumatism 59, 1540, 2008

  23. J Rheumatol36, 1273, 2009

  24. Effect of baseline characteristics on treatment response subjects achieving sUA <6.0 mg/dL at final visit (%) Febuxostat 40 mg/day n = 757 Allopurinol 200/300 mg/day n = 755 Febuxostat 80 mg/day n = 756 Arthritis Research & Therapy 12, R63, 2010

  25. Proportion of patients who achieved sUA < 6.0 mg/dL Clinical Therapeutics 35, 180, 2013

  26. Nota 91 • Determinazione 2 novembre 2010 (GU 12 novembre 2010, n. 265): • Modifiche, relative all’inserimento della Nota 91, alla determinazione 4 gennaio 2007 : “Note AIFA 2006-2007 per l’uso appropriato dei farmaci”. • La prescrizione a carico del SSN è limitata alle seguenti condizioni: • Trattamento dell'iperuricemia cronica con anamnesi o presenza di tofi e/o di artrite gottosa in soggetti che non siano adeguatamente controllati con allopurinolo o siano ad esso intolleranti.

  27. Xanthineoxidaseinhibitors allopurinol febuxostat Lancet 377, 165, 2011

More Related